Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study

por Yin, Sha, Chi, Yajing, Du, Yangyang, Wang, Jingfen, Shan, Changping, Yi, Weiwei, Shang, Mao, Man, Xiaochu, Tan, Qiaorui, Li, Huihui
Publicado 2022

Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer–The EARLY-MYO-BC study

por Chai, Yezi, Jiang, Meng, Wang, Yaohui, Liu, Qiming, Lu, Qifan, Tao, Zhengyu, Wu, Qizhen, Yin, Wenjin, Lu, Jinsong, Pu, Jun
Publicado 2023

Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective

por Ziobro, Marek, Grela-Wojewoda, Aleksandra
Publicado 2023

Integrin αvβ3 Is a Master Regulator of Resistance to TKI-Induced Ferroptosis in HER2-Positive Breast Cancer

por Nagpal, Aadya, Needham, Kristen, Lane, Darius J. R., Ayton, Scott, Redvers, Richard P., John, Melissa, Selistre-de-Araujo, Heloisa S., Denoyer, Delphine, Pouliot, Normand
Publicado 2023

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

por Dai, Ming Shen, Feng, Yin Hsun, Chen, Shang Wen, Masuda, Norikazu, Yau, Thomas, Chen, Shou Tung, Lu, Yen Shen, Yap, Yoon Sim, Ang, Peter C. S., Chu, Sung Chao, Kwong, Ava, Lee, Keun Seok, Ow, Samuel, Kim, Sung Bae, Lin, Johnson, Chung, Hyun Cheol, Ngan, Roger, Kok, Victor C., Rau, Kun Ming, Sangai, Takafumi, Ng, Ting Ying, Tseng, Ling Ming, Bryce, Richard, Bebchuk, Judith, Chen, Mei Chieh, Hou, Ming Feng
Publicado 2021

Septic arthritis and osteomyelitis due to Roseomonas; Case report and review of soft tissue, joint and bone infection

por Her, Minyoung
Publicado 2023

How Is COVID-19 Affecting South Korea? What Is Our Current Strategy?

por Her, Minyoung
Publicado 2020

Repurposing and reshaping of hospitals during the COVID-19 outbreak in South Korea

por Her, Minyoung
Publicado 2020

Her Excellency Ms Pamela Hamamoto, Ambassador, Permanent Representative of the United States of America to the United Nations Office and other International Organisations in Geneva

por Brice, Maximilien
Publicado 2015

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature

por Stanciu, Ioana-Miruna, Parosanu, Andreea Ioana, Orlov-Slavu, Cristina, Iaciu, Ion Cristian, Popa, Ana Maria, Olaru, Cristina Mihaela, Pirlog, Cristina Florina, Vrabie, Radu Constantin, Nitipir, Cornelia
Publicado 2023

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

por Grinshpun, Albert, Tolaney, Sara M., Burstein, Harold J., Jeselsohn, Rinath, Mayer, Erica L.
Publicado 2023

Multi-Targeting Anticancer Activity of a New 4-Thiazolidinone Derivative with Anti-HER2 Antibodies in Human AGS Gastric Cancer Cells

por Gornowicz, Agnieszka, Lesyk, Roman, Czarnomysy, Robert, Holota, Serhii, Shepeta, Yulia, Popławska, Bożena, Podolak, Magdalena, Szymanowski, Wojciech, Bielawski, Krzysztof, Bielawska, Anna
Publicado 2023

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy

por Lee, Eun-Gyeong, Lee, Dong-Eun, Kim, Hyun Hee, Han, Jai Hong, Lee, Seeyoun, Kang, Han-Sung, Lee, Eun Sook, Chae, Heejung, Sim, Sung Hoon, Lee, Keun Seok, Kwon, Youngmee, Jung, So-Youn
Publicado 2023

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing

por Ahn, Beung-Chul, Han, Ye-Jeong, Kim, Hye Ryun, Hong, Min Hee, Cho, Byoung Chul, Lim, Sun Min
Publicado 2023

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

por Arpino, Grazia, de la Haba Rodríguez, Juan, Ferrero, Jean-Marc, De Placido, Sabino, Osborne, C. Kent, Klingbiel, Dirk, Revelant, Valentine, Wohlfarth, Christine, Poppe, Raf, Rimawi, Mothaffar F.
Publicado 2023

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer

por Lavasani, Sayeh M., Somlo, George, Yost, Susan E., Frankel, Paul H., Ruel, Christopher, Cui, Yujie, Murga, Mireya, Tang, Aileen, Martinez, Norma, Kruper, Laura, Tumyan, Lusine, Schmolze, Daniel, Yeon, Christina, Yuan, Yuan, Waisman, James R., Mortimer, Joanne
Publicado 2022

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

por Cattaruzza, Fiore, Nazeer, Ayesha, To, Milton, Hammond, Mikhail, Koski, Caitlin, Liu, Lucas Y., Pete Yeung, V., Rennerfeldt, Deena A., Henkensiefken, Angela, Fox, Michael, Lam, Sharon, Morrissey, Kari M., Lange, Zachary, Podust, Vladimir N., Derynck, Mika K., Irving, Bryan A., Schellenberger, Volker
Publicado 2023

Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis

por Khoirunnisa, Sudewi Mukaromah, Suryanegara, Fithria Dyah Ayu, Setiawan, Didik, Postma, Maarten Jacobus
Publicado 2023